MLLCF Stock - Molecular Partners AG
Unlock GoAI Insights for MLLCF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $4.97M | $7.04M | $189.56M | $9.33M | $9.34M |
| Gross Profit | $-42,534,000 | $-40,806,000 | $139.66M | $-45,630,000 | $-46,731,000 |
| Gross Margin | -855.8% | -579.8% | 73.7% | -489.1% | -500.1% |
| Operating Income | $-61,217,000 | $-61,108,000 | $116.61M | $-63,418,000 | $-58,326,000 |
| Net Income | $-54,043,000 | $-61,984,000 | $117.85M | $-63,785,000 | $-62,764,000 |
| Net Margin | -1087.4% | -880.7% | 62.2% | -683.7% | -671.7% |
| EPS | $-1.63 | $-1.89 | $3.63 | $-2.06 | $-2.51 |
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Visit WebsiteEarnings History & Surprises
MLLCFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 4, 2026 | — | — | — | — |
Q4 2025 | Oct 30, 2025 | $-0.40 | $-0.40 | 0.0% | = MET |
Q3 2025 | Aug 25, 2025 | $-0.49 | $-0.55 | -11.0% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-0.41 | $-0.51 | -25.0% | ✗ MISS |
Q1 2025 | Mar 6, 2025 | $-0.43 | $-0.37 | +13.2% | ✓ BEAT |
Q4 2024 | Nov 1, 2024 | $-0.64 | $-0.58 | +9.6% | ✓ BEAT |
Q3 2024 | Aug 26, 2024 | — | $-0.51 | — | — |
Q2 2024 | Apr 17, 2024 | — | $-0.38 | — | — |
Q1 2024 | Mar 6, 2024 | — | $-0.70 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.38 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.54 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.50 | — | — |
Q1 2023 | Mar 9, 2023 | $-0.65 | $-0.52 | +19.4% | ✓ BEAT |
Q4 2022 | Oct 27, 2022 | $-0.61 | $-0.42 | +31.5% | ✓ BEAT |
Q3 2022 | Jul 13, 2022 | $-0.63 | $-0.15 | +76.9% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.65 | $4.99 | +867.9% | ✓ BEAT |
Q1 2022 | Mar 15, 2022 | $-0.62 | $-0.61 | +2.9% | ✓ BEAT |
Q4 2021 | Oct 28, 2021 | $-0.55 | $-0.38 | +30.9% | ✓ BEAT |
Q3 2021 | Aug 26, 2021 | $-0.57 | $-0.61 | -6.8% | ✗ MISS |
Q2 2021 | May 3, 2021 | — | $-0.60 | — | — |
Latest News
Frequently Asked Questions about MLLCF
What is MLLCF's current stock price?
What is the analyst price target for MLLCF?
What sector is Molecular Partners AG in?
What is MLLCF's market cap?
Does MLLCF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to MLLCF for comparison